IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Polaris Venture Management Co. V, L.L.C.

Q3 2018 Holdings

Filed 2018-11-13 | 12 holdings | $199.7K | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Cardlytics, Inc.(CDLX)Common Stock14161W105$63.9K2,552,62632.0%
Fate Therapeutics, Inc.(FATE)Common Stock31189P102$40.3K2,473,18620.2%
Neuronetics, Inc.(STIM)Common Stock64131A105$26.4K824,76513.2%
Selecta Biosciences, Inc.(SELBUSD)Common Stock816212104$25.0K1,606,81312.5%
Kala Pharmaceuticals, Inc.Common Stock483119103$18.3K1,857,5829.2%
T2 Biosystems, Inc.Common Stock89853L104$13.7K1,841,9246.9%
Trevena, Inc.Common Stock89532E109$4.4K2,053,5402.2%
Arsanis, Inc.Common Stock042873109$3.0K1,868,9571.5%
Genocea Biosciences, Inc.Common Stock372427104$1.5K1,968,6060.8%
Atyr Pharma Inc.(LIFEUSD)Common Stock002120103$1.5K1,827,9920.7%
Pulmatrix, Inc.Common Stock74584P103$1.3K3,594,3810.7%
Dare Bioscience, Inc.(CERUEUR)Common Stock23666P101$318326,2430.2%